BioCentury | Jan 13, 2014
Company News

Medytox, Allergan deal

...Korea to develop and commercialize undisclosed neurotoxin products from Medytox (see BioCentury Sept 30, 2013). Medytox Inc....
BioCentury | Sep 30, 2013
Company News

Medytox, Allergan deal

...grant Allergan exclusive, worldwide rights outside of Korea to develop and commercialize undisclosed neurotoxin products. Medytox...
...in milestones, plus royalties. Allergan declined to provide details, and Medytox could not be reached. Medytox Inc....
BioCentury | Sep 30, 2013
Finance

Regulatory milestones

...Phase II testing to treat psoriasis. Top-line data are expected in 1Q14. South Korean biotech Medytox Inc....
...will receive exclusive, worldwide rights outside of Korea to develop and commercialize undisclosed neurotoxin products. Medytox...
...upfront payment of $65 million and is eligible for $297 million in milestones, plus royalties. Medytox...
BioCentury | Sep 27, 2013
Company News

Allergan, Medytox in neurotoxin product deal

...South Korean biotech Medytox Inc. (KOSDAQ:086900) gained W17,000 (12%) to W155,000 on Thursday after it and Allergan...
...will receive exclusive, worldwide rights outside of Korea to develop and commercialize undisclosed neurotoxin products. Medytox...
...is eligible for $297 million in milestones, plus royalties. Allergan declined to provide details and Medytox...
Items per page:
1 - 4 of 4
BioCentury | Jan 13, 2014
Company News

Medytox, Allergan deal

...Korea to develop and commercialize undisclosed neurotoxin products from Medytox (see BioCentury Sept 30, 2013). Medytox Inc....
BioCentury | Sep 30, 2013
Company News

Medytox, Allergan deal

...grant Allergan exclusive, worldwide rights outside of Korea to develop and commercialize undisclosed neurotoxin products. Medytox...
...in milestones, plus royalties. Allergan declined to provide details, and Medytox could not be reached. Medytox Inc....
BioCentury | Sep 30, 2013
Finance

Regulatory milestones

...Phase II testing to treat psoriasis. Top-line data are expected in 1Q14. South Korean biotech Medytox Inc....
...will receive exclusive, worldwide rights outside of Korea to develop and commercialize undisclosed neurotoxin products. Medytox...
...upfront payment of $65 million and is eligible for $297 million in milestones, plus royalties. Medytox...
BioCentury | Sep 27, 2013
Company News

Allergan, Medytox in neurotoxin product deal

...South Korean biotech Medytox Inc. (KOSDAQ:086900) gained W17,000 (12%) to W155,000 on Thursday after it and Allergan...
...will receive exclusive, worldwide rights outside of Korea to develop and commercialize undisclosed neurotoxin products. Medytox...
...is eligible for $297 million in milestones, plus royalties. Allergan declined to provide details and Medytox...
Items per page:
1 - 4 of 4